JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120032

(±)-Thalidomide, Immunomodulator and anticancer agent

Be the first to review this product! Submit a review

|

(3 Publications)

MW 258.23 Da, Purity >99%. Immunomodulator. Antiproliferative, antiangiogenic and pro-apoptotic. Achieve your results faster with highly validated, pure and trusted compounds.

View Alternative Names

2610203G15Rik, 2900045O07Rik, AF229032, AW108261, CRBN_HUMAN, Cereblon, DKFZp781K0715, MGC27358, MRT2A, OTTHUMP00000209555, Protein cereblon, Protein x 0001, piL

1 Images
Chemical Structure - (±)-Thalidomide, Immunomodulator and anticancer agent (AB120032)
  • Chemical Structure

Lab

Chemical Structure - (±)-Thalidomide, Immunomodulator and anticancer agent (AB120032)

2D chemical structure image of ab120032, Thalidomide, Immunomodulator and anticancer agent

Key facts

CAS number

50-35-1

Purity

>99%

Form

Solid

form

Molecular weight

258.23 Da

Molecular formula

C<sub>1</sub><sub>3</sub>H<sub>1</sub><sub>0</sub>N<sub>2</sub>O<sub>4</sub>

PubChem

5426

Nature

Synthetic

Solubility

Soluble in DMSO to 25 mM

Biochemical name

Thalidomide

Biological description

Immunomodulator. Antiproliferative, antiangiogenic and pro-apoptotic.

Canonical smiles

C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O

InChi

InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)

InChiKey

UEJJHQNACJXSKW-UHFFFAOYSA-N

IUPAC Name

2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CRBN also known as cereblon is a protein involved in the regulation of protein homeostasis. It has a molecular weight of approximately 51 kDa. CRBN is expressed in various tissues including the brain kidney and muscle. It functions as a substrate receptor for the CRL4-CRBN E3 ubiquitin ligase complex recognizing proteins for ubiquitination and degradation. The chemical structure of thalidomide shows binding affinity to CRBN influencing its function.
Biological function summary

Cereblon plays a role in the regulation of protein stability and degradation. It forms part of the CRL4-CRBN complex which tags specific proteins for ubiquitination and subsequent proteasomal degradation. This function is critical for maintaining cellular protein balance. Additionally CRBN modulates immune response and has immunomodulator properties influencing cell-mediated responses.

Pathways

CRBN participates in the ubiquitin-proteasome pathway which regulates protein turnover and quality control within cells. Moreover CRBN is involved in immune signaling pathways partly by modulating the expression of various cytokines and immune-related proteins. It interacts with proteins such as DDB1 and CUL4 within these pathways impacting cellular responses to stress and immune challenges.

CRBN is associated with multiple myeloma and intellectual disability. Cereblon acts as a target for drugs like thalidomide and lenalidomide which are used in the treatment of multiple myeloma by altering ubiquitination processes. In intellectual disability alterations in CRBN function or expression can disrupt neuronal development and signaling. CRBN interacts with proteins like IKZF1 and IKZF3 within these contexts affecting their roles in disease progression and treatment responses.

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

iScience 26:107059 PubMed37360684

2023

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells.

Applications

Unspecified application

Species

Unspecified reactive species

Habib Bouguenina,Stephanos Nicolaou,Yann-Vaï Le Bihan,Elizabeth A Bowling,Cheyenne Calderon,John J Caldwell,Brinley Harrington,Angela Hayes,P Craig McAndrew,Costas Mitsopoulos,Fernando Jr Sialana,Andrea Scarpino,Mark Stubbs,Arjun Thapaliya,Siddhartha Tyagi,Hannah Z Wang,Francesca Wood,Rosemary Burke,Florence Raynaud,Jyoti Choudhary,Rob L M van Montfort,Amine Sadok,Thomas F Westbrook,Ian Collins,Rajesh Chopra

Frontiers in medicine 9:899998 PubMed35733868

2022

The Type I Interferon Pathway Is Upregulated in the Cutaneous Lesions and Blood of Multibacillary Leprosy Patients With Erythema Nodosum Leprosum.

Applications

Unspecified application

Species

Unspecified reactive species

Thabatta Leal Silveira Andrezo Rosa,Mayara Abud Mendes,Natasha Ribeiro Cardoso Linhares,Thais Fernanda Rodrigues,André Alves Dias,Thyago Leal-Calvo,Mariana Gandini,Helen Ferreira,Fabrício da Mota Ramalho Costa,Anna Maria Sales,Thaís Porto Amadeu,Veronica Schmitz,Roberta Olmo Pinheiro,Luciana Silva Rodrigues,Milton Ozório Moraes,Maria Cristina Vidal Pessolani

Oncotarget 8:88670-88688 PubMed29179466

2017

Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action.

Applications

Unspecified application

Species

Unspecified reactive species

Lewis A Quayle,Maria G Pereira,Gerjan Scheper,Tammy Wiltshire,Ria E Peake,Issam Hussain,Carol A Rea,Timothy E Bates
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com